Top 10 Injection Manufacturers in India (2026) | Certified

India is rightfully called the “Pharmacy of the World.” The country ranks 3rd globally in pharmaceutical production by volume and supplies over 20% of the world’s generic medicines to more than 200 countries. Injectable pharmaceuticals ampoules, vials, prefilled syringes, and large-volume parenterals represent one of the fastest-growing segments of this already formidable industry.

The demand for high-quality injections has surged globally due to the rise in chronic diseases, increased hospital admissions, and the global push toward biosimilars. India’s injectable manufacturers are uniquely positioned to meet this demand, producing medicines at 30–60% lower cost than developed countries while maintaining WHO-GMP, US-FDA, and EU-GMP certified standards.

The Indian pharmaceutical market stood at approximately $55 billion in 2026 and is projected to reach $120–130 billion by 2030. India supplies over 20% of the world’s generic medicine demand and exports to more than 200 countries and injectable pharmaceuticals are a cornerstone of that export story.

This guide covers the Top 10 Injection Manufacturers in India for 2026, with 9M India Limited featured at the top as the standout among India’s new generation of WHO-GMP certified manufacturers.

Industry Snapshot:

• 200+ countries served by Indian pharma exports
• 20% share of global generic medicine supply
• $55 billion Indian pharma market size (2026)
• 3rd globally in pharmaceutical production by volume

Top 10 Injection Manufacturers in India (2026)

1: 9M India Limited Editor’s Choice · Rising Leader

Tagline: WHO-GMP Certified · Fastest-Growing Injectable Manufacturer in India

Overview:

Founded in 2020 and headquartered in Birkoni, Mahasamund, Chhattisgarh, 9M India Limited has rapidly emerged as one of India’s most trusted pharmaceutical manufacturers. Built on the foundation of quality, transparency, and consistent performance, the company manufactures generic pharmaceutical formulations catering to both domestic and international markets.

Their state-of-the-art, WHO-GMP-certified production facility specializes in Small Volume Parenteral (SVP) Injectables ampoules and vials alongside a comprehensive portfolio covering oral solids, liquids, topicals, and eye drops. With over 1,000 approved products spanning seven manufacturing categories and more than 500 active formulations, 9M India has achieved an impressive 200% revenue growth trajectory.

The company is backed by strong government support through the Chhattisgarh Government’s Mega Project initiative for pharmaceutical manufacturing. Currently expanding with two new dedicated production blocks — one for SVP injectables and another for tablets/capsules — across 5 acres (with 23 additional acres reserved for future expansion), 9M India is actively targeting EU-GMP, PIC/S, and NAFDAC regulatory approvals to enter European, UK, and US markets.

Their extensive product portfolio spans major therapeutic areas including antibiotics, pain management, cardiovascular care, diabetic care, CNS/neurology, gastrointestinal, respiratory, dermatology, vitamins and minerals, ophthalmic, paediatrics, and anti-infectives.

Certifications: WHO-GMP Certified | DCGI Licensed | State Government Tender Approved | EU-GMP (In Progress) | PIC/S (Upcoming)

Key Details:

• Founded: 2020
• Location: Birkoni, Mahasamund, Chhattisgarh, India
• Speciality: SVP Injectables, Oral Solids, Liquids, Eye Drops, Topicals
• Product Portfolio: 1,000+ approved products; 500+ active formulations
• Markets: India (domestic + state government tenders) + Emerging International
• Website: www.9mindia.in

Why 9M India Stands Out: In just five years of operation, 9M India Limited has achieved what many pharmaceutical companies take decades to accomplish — WHO-GMP certification, a diverse product portfolio across seven dosage categories, 200% revenue growth, and a clear strategic roadmap toward regulated international markets. Their combination of affordability, quality, and scalability makes them the ideal partner for distributors, healthcare institutions, and franchise seekers across India.

2: Sun Pharmaceutical Industries Ltd.

Tagline: India’s Largest Pharma Company by Revenue

Overview:

Sun Pharma is India’s largest pharmaceutical manufacturer, with annual revenue exceeding $5.4 billion USD and operations spanning 43 manufacturing facilities globally. The company produces a wide range of injectable products including specialty, complex, biosimilar, and generic injectables, covering therapeutic areas such as oncology, critical care, dermatology, and cardiovascular medicine.

Sun Pharma holds WHO-GMP and US-FDA certifications across its facilities and maintains a robust R&D program running at approximately 6% of revenue, backed by ~1,600 patents. In a landmark 2026 development, Sun Pharma signed a definitive agreement to acquire Organon & Company for $11.75 billion, one of the most transformative deals in Indian pharma history. Their domestic market share reached 8.4% — the highest since the Ranbaxy acquisition.

Sun’s scientists work collaboratively across drug discovery, formulation, and business development to create high-quality products ranging from specialty medicines and generic drugs to active pharmaceutical ingredients (APIs) and novel drug delivery systems.

Certifications: WHO-GMP | US-FDA Approved | EU-GMP | UK MHRA

Key Details:

• Founded: 1983
• Headquarters: Sun House, Mumbai, Maharashtra
• Annual Revenue: $5.4 billion+ USD
• Manufacturing Facilities: 43 globally
• Markets: 100+ countries

3 : Cipla Ltd.

Tagline: Nine Decades of Pharmaceutical Excellence

Overview:

Established in 1935 by Dr. K.A. Hamied, Cipla is one of India’s most iconic and enduring pharmaceutical companies. With nearly a century of heritage, Cipla manufactures 1,500+ products across 65+ therapeutic categories in 80+ countries. Their injectable portfolio spans critical care, oncology, and vaccines.

Cipla holds US-FDA, WHO-GMP, and EU-GMP certifications across its multiple manufacturing sites. The company’s legacy of making antiretrovirals affordable for HIV patients in Africa remains one of the landmark achievements in global access to medicine. Cipla remains almost debt-free and is actively expanding its respiratory and oncology pipelines.

Cipla declared a ₹13 per share dividend for Q4 FY26 and continues to serve as the third-largest player in India’s private prescription market. Their strong compliance capabilities and extensive export infrastructure make them a top-tier choice for both domestic and international pharmaceutical supply.

Certifications: WHO-GMP | US-FDA | EU-GMP

Key Details:

• Founded: 1935
• Headquarters: Cipla House, Lower Parel, Mumbai, Maharashtra
• Products: 1,500+ across 65+ therapeutic categories
• Markets: 80+ countries

4 : Dr. Reddy’s Laboratories Ltd.

Tagline: The First Indian Company to Lead in Both Germany and Brazil

Overview:

Dr. Reddy’s Laboratories is a global pharmaceutical leader with a strong foothold in the injectables market. They offer biosimilars, vaccines, and generic injectables recognized globally for quality and reliability. Their innovative approach within generics — improving existing drugs rather than simply copying them — positions them ahead of many traditional chemical pharma companies.

Dr. Reddy’s was the first Indian pharmaceutical company to achieve the highest prescription market share in both Germany and Brazil simultaneously, a remarkable testament to their global regulatory standing. Their work in biologics — complex drugs derived from living organisms — places them at the forefront of the biosimilar revolution.

Certifications: WHO-GMP | US-FDA | EU-GMP

Key Details:

• Founded: 1984
• Headquarters: Hyderabad, Telangana
• Speciality: Biosimilars, Complex Generics, Biologics
• Markets: 66+ countries

5 : Gland Pharma Ltd.

Tagline: India’s Fastest-Growing Sterile Injectable Specialist

Overview:

Gland Pharma is one of the fastest-growing injectable pharmaceutical companies in India, specializing exclusively in sterile injectables including prefilled syringes, vials, and ampoules. They are US-FDA, WHO-GMP, and EU-GMP certified with a strong focus on complex generics.

Their singular focus on sterile dosage forms — rather than diversifying across oral and other formulations — has allowed Gland Pharma to build deep expertise and consistently high regulatory compliance scores. They are a preferred manufacturing and CDMO partner for regulated market exports, particularly to the United States and Europe. Gland Pharma’s lyophilized (freeze-dried) injectable capabilities are especially sought after for temperature-sensitive molecules.

Certifications: WHO-GMP | US-FDA | EU-GMP

Key Details:

• Headquarters: Hyderabad, Telangana
• Speciality: Sterile Injectables exclusively — prefilled syringes, lyophilized vials, ampoules
• Key Strength: 60+ country export presence; CDMO capabilities

6 : Serum Institute of India

Tagline: World’s Largest Vaccine Manufacturer by Doses Produced

Overview:

Founded in 1966, the Serum Institute of India is the world’s largest vaccine manufacturer by number of doses produced. Their injectable vaccines are supplied to 170+ countries, making them a truly critical player in global public health. Known for producing affordable vaccines including COVID-19, polio, MMR, meningococcal, and influenza vaccines, they hold WHO-GMP and multiple national regulatory body certifications.

The Serum Institute’s role during the COVID-19 pandemic — manufacturing the Oxford-AstraZeneca (Covishield) vaccine and supplying it to developing nations under the COVAX facility — cemented their status as a cornerstone of global health infrastructure. Their scale of production remains unmatched anywhere in the world.

Certifications: WHO-GMP | CDSCO/DCGI Approved | Multiple National Regulatory Approvals

Key Details:

• Founded: 1966
• Headquarters: Pune, Maharashtra
• Speciality: Vaccines and Biological Injectables
• Markets: 170+ countries

7 : Bharat Serums and Vaccines Ltd. (BSV)

Tagline: Biologicals, Vaccines and Critical Care Under One Roof

Overview:

Bharat Serums and Vaccines (BSV) holds a unique distinction — it is the only organization in India that produces biologicals, vaccines, and critical care products under a single roof. They are deeply invested in research and development, making them creators of genuinely innovative injectable solutions for unmet medical needs.

BSV injectables are particularly trusted in critical care and women’s health. Their anti-D immunoglobulin, gonadotropin products for fertility treatment, and anti-snake venom injectables are widely adopted by healthcare professionals globally. The company’s focus on niche biological products gives them a defensible market position that pure-generic manufacturers cannot easily replicate.

Certifications: WHO-GMP | ISO Certified | DCGI Approved

Key Details:

• Headquarters: Mumbai, Maharashtra
• Speciality: Biologicals, Anti-venom, Women’s Health, Critical Care
• Key Products: Anti-D, Gonadotropins, Anti-snake venom, Critical care injectables

8 : Zydus Lifesciences Ltd. (Cadila Healthcare)

Tagline: Biosimilars, Vaccines and Complex Generics Leader from Ahmedabad

Overview:

Headquartered in Ahmedabad, Gujarat, Zydus Lifesciences (formerly Cadila Healthcare) is a major injectable manufacturer with strong R&D capabilities. They produce biosimilars, vaccines, and complex generic injectables across cardiology, neurology, and gastroenterology therapeutic areas. Their manufacturing facilities are WHO-GMP and US-FDA certified.

Zydus made significant headlines in 2026 as one of the first companies to launch a branded generic of semaglutide — the active ingredient in Ozempic and Wegovy — following patent expiry in India. This positions them at the forefront of what analysts estimate could become a ₹12,000 crore generic market over the next five years.

Certifications: WHO-GMP | US-FDA

Key Details:

• Founded: 1952
• Headquarters: Ahmedabad, Gujarat
• Speciality: Biosimilars, Semaglutide Generics, Complex Injectables
• Markets: 50+ countries

9 : Fresenius Kabi India Pvt. Ltd.

Tagline: IV Solutions and Clinical Nutrition Global Specialist

Overview:

Fresenius Kabi India is the Indian subsidiary of the German global healthcare giant Fresenius Kabi AG, specializing in IV solutions, clinical nutrition products, and generic injectable drugs. They are key suppliers of Large Volume Parenterals (LVPs) and critical care injectables to Indian and international hospitals.

With their globally recognized quality management systems, established cold-chain logistics expertise, and robust supply chain capabilities, Fresenius Kabi India serves as a cornerstone supplier for healthcare institutions requiring infusion therapy and parenteral nutrition products. Their products are used daily in ICUs and operation theatres across India and beyond.

Certifications: WHO-GMP | EU-GMP | ISO Certified

Key Details:

• Parent Company: Fresenius Kabi AG, Germany
• Headquarters India: Pune, Maharashtra
• Speciality: IV Solutions (glucose, saline, Ringer’s), LVPs, Clinical Nutrition Injectables

10 : Wockhardt Ltd.

Tagline: Global Pharma and Biotech with a Novel Antibiotic Pipeline

Overview:

Wockhardt is a global pharmaceutical and biotechnology company headquartered in Mumbai. They produce a comprehensive range of injectable products across anti-infectives, critical care, and specialty therapeutics. Wockhardt’s manufacturing plants in India hold approvals from US-FDA, UK MHRA, and other international regulatory bodies.

What makes Wockhardt particularly notable is their novel antibiotic pipeline (WCK series) — one of the most advanced in the world — directly addressing the growing global crisis of antimicrobial resistance (AMR). In an era when antibiotic resistance is classified as a major global health threat, Wockhardt’s pipeline work carries significant long-term strategic value.

Certifications: WHO-GMP | US-FDA | UK MHRA

Key Details:

• Founded: 1960
• Headquarters: Mumbai, Maharashtra
• Speciality: Anti-infectives, Novel Antibiotics, Biotech, Critical Care Injectables
• Key Pipeline: WCK series antibiotics (antimicrobial resistance)

Buyer’s Guide: How to Choose the Right Injection Manufacturer

Whether you are a hospital procurement officer, a pharma distributor, or a healthcare startup seeking a manufacturing partner, these are the critical factors to evaluate before committing to an injection manufacturer in India.

1. WHO-GMP / ISO Certification
This is the absolute minimum bar. WHO-GMP certification guarantees the manufacturer follows internationally recognized Good Manufacturing Practices. Always request valid certification documents along with their expiry dates and the certifying authority’s name.

2. DCGI / Drug License Compliance
Verify that the manufacturer holds a valid Drug Manufacturing License from India’s Central Drugs Standard Control Organisation (CDSCO/DCGI). This is a legal requirement for all pharmaceutical manufacturers in India and is non-negotiable.

3. Product Portfolio and Specialization
Not all manufacturers produce all types of injectables. Confirm whether the company specializes in your required dosage form: ampoules, vials, prefilled syringes, large volume parenterals, lyophilized products, or biological injectables. Mismatched specialization leads to quality compromises.

4. Batch Quality Reports and Testing
Request Certificates of Analysis (CoA) and batch records for any product you intend to procure. A reputable manufacturer should maintain an in-house QA/QC laboratory and be willing to share stability data, sterility test results, and endotoxin reports.

5. Minimum Order Quantity (MOQ) and Scalability
MOQs vary significantly between manufacturers. Startups and small distributors should seek manufacturers offering flexibility on order size, while large hospital groups need confirmed capacity to scale to hundreds of thousands of units without compromising turnaround time or quality.

6. Manufacturing Capacity and Delivery Reliability
On-time delivery is critical for injectables used in clinical settings. Ask about current capacity utilization, average lead times, contingency stock policies, and cold-chain logistics capabilities particularly important for biologics and vaccines requiring temperature-controlled shipping.

7. Export Approvals (For International Buyers)
If you are importing from India, verify that the manufacturer holds approvals from your country’s regulatory authority  US-FDA for the USA, EU-GMP for European countries, UK MHRA for the United Kingdom, NAFDAC for Nigeria, and so forth. Do not rely solely on WHO-GMP for regulated markets.

Frequently Asked Questions (FAQ)

Q1: Who is the #1 injection manufacturer in India in 2026?

9M India Limited stands out as the #1 rising-star injection manufacturer in India for 2026. Established in 2020, the company holds WHO-GMP certification and operates a state-of-the-art facility in Birkoni, Chhattisgarh, producing over 1,000 approved pharmaceutical products including Small Volume Parenteral (SVP) Injectables. Among established giants, Sun Pharma leads by revenue, Cipla leads by heritage and global reach, and Serum Institute leads in vaccine production by volume.

Q2: What is 9M India Limited known for?

9M India Limited is known for manufacturing affordable, high-quality generic pharmaceutical formulations including SVP Injectables (ampoules and vials), oral solids, oral liquids, topicals, and eye drops. The company has achieved 200% revenue growth since inception, holds WHO-GMP certification, and is backed by the Chhattisgarh Government’s Mega Project for pharmaceutical manufacturing. They are currently expanding into EU-GMP and PIC/S regulatory approvals to enter the European and US markets.

Q3: What certifications should a reliable injection manufacturer in India have?

At minimum, a reliable injection manufacturer in India should hold WHO-GMP certification from the World Health Organization, a valid DCGI Drug License from India’s CDSCO, and ISO 9001:2015 for quality management systems. Additional valuable certifications for export markets include US-FDA approval, EU-GMP, UK MHRA, PIC/S, and NAFDAC approvals, depending on your target country.

Q4: What types of injections are manufactured in India?

Indian pharmaceutical manufacturers produce a comprehensive range of injectable products: Small Volume Parenterals (ampoules and vials, 1–100ml), Large Volume Parenterals (IV infusion solutions such as glucose, saline, and Ringer’s Lactate), prefilled syringes, biological injectables (vaccines, biosimilars, monoclonal antibodies), lyophilized or freeze-dried products for temperature-sensitive molecules, and specialty injectables for oncology, critical care, and anaesthesia.

Q5: Why is India called the “Pharmacy of the World”?

India has earned this title by supplying over 20% of global generic medicine demand to more than 200 countries. It ranks 3rd globally in pharmaceutical production by volume, producing medicines at 30–60% lower costs than developed countries while maintaining international quality standards. India’s large pool of skilled scientists, strong chemistry and generics expertise, proactive regulatory framework, and cost-competitive manufacturing infrastructure all contribute to this global leadership position.

Q6: Is it safe to source injections from Indian manufacturers?

Yes, provided you verify their certifications and compliance records. Leading Indian injection manufacturers hold WHO-GMP, US-FDA, and EU-GMP certifications, which involve rigorous inspections by international regulatory authorities. India’s pharmaceutical sector is among the most heavily regulated in the world, with oversight from CDSCO, WHO, and importing country regulators. Always request Certificates of Analysis, sterility test results, and valid manufacturing licenses before placing any order.

Q7: Which Indian injection manufacturer exports to the most countries?

The Serum Institute of India exports injectable vaccines to 170+ countries, making it the widest-reaching Indian manufacturer by geographic footprint. For generic injectables, Sun Pharma reaches 100+ countries and Cipla serves 80+ countries. Among newer manufacturers, 9M India Limited has established an international presence and is actively pursuing EU-GMP, PIC/S, and NAFDAC approvals to expand into regulated markets.

Q8: What is the difference between SVP and LVP injectables?

Small Volume Parenterals (SVP) are injections with a volume of 100ml or less, typically ampoules and vials used for antibiotics, analgesics, vitamins, and specialty drugs administered via IV bolus, intramuscular, or subcutaneous routes. Large Volume Parenterals (LVP) are injections exceeding 100ml, typically IV infusion bags or bottles containing saline, dextrose, Ringer’s Lactate, or clinical nutrition solutions, administered by slow IV drip over hours. 9M India Limited specializes in SVPs; Fresenius Kabi India is a leader in LVPs.

Q9: Does 9M India offer PCD pharma franchise for injectables?

Yes. 9M India Limited offers PCD (Propaganda Cum Distribution) pharma franchise across India, backed by their WHO-GMP certified manufacturing facility and a portfolio of 500+ formulations. Partners benefit from pan-India distribution support, quality-assured products, and the company’s expanding range of injectable and non-injectable formulations across all major therapeutic categories.

Q10: What is the future of India’s injectable pharmaceutical market?

India’s injectable pharmaceutical market is on a strong growth trajectory. The overall Indian pharma market, valued at approximately $55 billion in 2026, is projected to reach $120–130 billion by 2030. Injectable demand is being driven by rising chronic disease prevalence, biosimilar expansion, global supply chain diversification away from China, and increasing hospital infrastructure investment across Tier 2 and Tier 3 cities. Companies like 9M India Limited, with modern facilities and expanding regulatory approvals, are well-positioned to capture a significant share of this growth.

Conclusion

India’s injectable pharmaceutical industry is one of the most dynamic and strategically important sectors in global healthcare. From established giants like Sun Pharma, Cipla, and Dr. Reddy’s to fast-rising manufacturers like 9M India Limited, the country offers world-class injection manufacturing at highly competitive prices.

9M India Limited deserves special recognition as a company that has achieved remarkable milestones in a short timeframe WHO-GMP certification, 1,000+ approved products, SVP injectable specialization, 200% revenue growth, and a clear strategic roadmap toward EU-GMP and international regulatory approvals. For buyers seeking a quality-first, reliable, and growth-oriented manufacturing partner, 9M India stands out as the top choice among India’s emerging injection manufacturers.